ALLMedicine™ Ankylosing Spondylitis Center
Research & Reviews 7,913 results
https://doi.org/10.1007/s00296-021-04863-x 10.1038/s41584-020-00527-5 10.2807/1560-7917.ES.2020.25.12.2000293 10.1016/S0140-6736(20)30627-9 10.1136/annrheumdis-2019-216655 10.1093/rheumatology/keaa554 10.1007/s00296-020-04648-8 10.1136/annrheumdis-2020-218165 10.5435/JAAOS-D-20-00380 10.1093/jamia/ocaa072 10.1089/tmj.2009.9960 10.1136/bmjopen-2017-016242 10.1007/s11882-018-0808-4 10.1093/rheumatology/keaa218 10.1007/s10067-020-05312-z 10.2196/resprot.5631 10.1002/acr.20621 10.1007/s00296-020-04737-8 10.1136/rmdopen-2020-001314 10.5334/ijic.1990 10.1136/annrheumdis-2020-217548 10.1016/j.semarthrit.2016.05.013 10.1016/j.rdc.2016.01.002 10.1016/j.rdc.2016.01.010
Rheumatology International; Chevallard M, Belloli L et. al.
May 4th, 2021 - Close follow-up is mandatory in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). During the Coronavirus Disease 2019 (COVID-19) pandemic, rheumatological care was rapidly reorganized during the f...
https://www.ncbi.nlm.nih.gov/pubmed/33938794
Clinical and Experimental Rheumatology; Su J, Wang R et. al.
May 3rd, 2021 - The objective of this study is to describe the clinical features of patients with axial spondyloarthritis (axial SpA) in the ChinaSpA registry. Patients with clinical diagnosis of ankylosing spondylitis (AS) or axial SpA were enrolled into the reg...
https://doi.org/10.1007/s10067-021-05713-8
Clinical Rheumatology; Merola JF, Dennis N et. al.
May 2nd, 2021 - To compare healthcare resource utilization and costs among patients with psoriasis, psoriatic arthritis (PsA), and a control group of patients without psoriasis and PsA in the USA. The IBM® MarketScan® Commercial Database was used to identify thre...
https://doi.org/10.1111/ijcp.14279
International Journal of Clinical Practice; Akaltun MS, Altindag O et. al.
Apr 29th, 2021 - The objective of the present study was to investigate the effect of the Pulmonary Rehabilitation Program on work productivity, disease activity, functional status, quality of life, Respiratory Function Tests (RFTs), physical capacity,and depressio...
https://doi.org/10.1007/s10067-021-05739-y 10.1016/j.rdc.2015.07.001 10.1002/acr.20363 10.1097/rhu.0000000000000721 10.3899/jrheum.140021 10.5152/eurjrheum.2017 10.1002/acr.22926 10.1155/2012/714321 10.1016/j.jbspin.2019.12.004 10.1136/annrheumdis-2015-208466 10.1136/annrheumdis-2014-205675 10.1136/annrheumdis-2018-213585 10.1016/j.apmr.2017.07.015 10.1002/art.39573 10.1002/acr.23614 10.1136/rmdopen-2018-000729 10.1007/s00296-014-3141-9 10.2165/00007256-200838110-00003 10.1002/acr.21780 10.1016/j.hkpj.2015.10.001 10.3899/jrheum.180782 10.1007/s10067-017-3917-x 10.3109/03009749409103722 10.1016/j.semarthrit 10.1016/j.jbspin.2015.07.017 10.1016/j.atherosclerosis.2018.03.004 10.1111/echo.14103 10.1136/heartjnl-2015-307838 10.1136/annrheumdis-2013-203291 10.1007/s00296-018-4183-1 10.1111/joim.12715 10.1007/s10067-016-3304-z 10.1136/rmdopen-2017-000486 10.1589/jpts.28.2005 10.1136/annrheumdis-2013-203643 10.1007/s10067-013-2436-7 10.3899/jrheum.160715 10.3899/jrheum.190540 10.1007/s10067-014-2791-z 10.1111/jocn.12353 10.3109/09638281003649946 10.1093/rheumatology/ken380 10.1111/jocn.14606 10.1016/j.semarthrit.2019.10.002 10.1093/rheumatology/ken410 10.3899/jrheum.151244 10.3899/jrheum.080375 10.1016/s0196-0644(96)70238-x 10.1001/archdermatol.2012.943 10.1111/jdv.12607 10.1111/bjd.12735 10.1111/bjd.17741 10.1002/acr.24121 10.1136/annrheumdis-2017-212004 10.1002/art.39458 10.1007/s40744-021-00298-9
Clinical Rheumatology; Kessler J, Chouk M et. al.
Apr 29th, 2021 - The positive effects of physical activity in both rheumatoid arthritis and ankylosing spondylitis have been proven, but no clear data is yet published regarding psoriatic arthritis (PsA). The aims of this study were (i) to assess the level of phys...
Guidelines 37 results
https://www.rheumatology.org/Portals/0/Files/AxialSpA-Guideline-2019.pdf
Ward MM,et al
Sep 30th, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). ankylosing spondylitis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764882
Arthritis & Rheumatology (Hoboken, N.J.); Ward MM, Deodhar A et. al.
Aug 22nd, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). We conducted updated systematic literature reviews for 20 clinical questions on pharmacologi...
https://www.businesswire.com/news/home/20190723006033/en/FDA-Approves-Samsung-Bioepis-HADLIMA%E2%84%A2-adalimumab-bwwd
Jul 23rd, 2019 - Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® i (adalimumab), for the treatment of rheumatoid arthritis, juvenile idiopathic arthr...
http://www.samsungbioepis.com/en/newsroom/detail/FDA-Approves-ETICOVO-Samsung-Bioepis-Second-Anti-TNF-Medicine.html
Apr 28th, 2019 - Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved ETICOVO™ (etanercept-ykro), a biosimilar referencing ENBREL® (etanercept), across all eligible indications for the treatment of rheumatoid arthri...
https://www.rheumatology.org/Portals/0/Files/ACR-AAHKS-Perioperative-Management-Guideline.pdf
Goodman, S.,et al
Jul 31st, 2017 - This collaboration between the American College of Rheumatology and the American Association of Hip and Knee Surgeons developed an evidence-based guideline for the perioperative management of antirheumatic drug therapy for adults with rheumatoid a.
Drugs 1,139 results see all →
Clinicaltrials.gov 9,549 results
https://doi.org/10.1007/s00296-021-04863-x 10.1038/s41584-020-00527-5 10.2807/1560-7917.ES.2020.25.12.2000293 10.1016/S0140-6736(20)30627-9 10.1136/annrheumdis-2019-216655 10.1093/rheumatology/keaa554 10.1007/s00296-020-04648-8 10.1136/annrheumdis-2020-218165 10.5435/JAAOS-D-20-00380 10.1093/jamia/ocaa072 10.1089/tmj.2009.9960 10.1136/bmjopen-2017-016242 10.1007/s11882-018-0808-4 10.1093/rheumatology/keaa218 10.1007/s10067-020-05312-z 10.2196/resprot.5631 10.1002/acr.20621 10.1007/s00296-020-04737-8 10.1136/rmdopen-2020-001314 10.5334/ijic.1990 10.1136/annrheumdis-2020-217548 10.1016/j.semarthrit.2016.05.013 10.1016/j.rdc.2016.01.002 10.1016/j.rdc.2016.01.010
Rheumatology International; Chevallard M, Belloli L et. al.
May 4th, 2021 - Close follow-up is mandatory in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). During the Coronavirus Disease 2019 (COVID-19) pandemic, rheumatological care was rapidly reorganized during the f...
https://www.ncbi.nlm.nih.gov/pubmed/33938794
Clinical and Experimental Rheumatology; Su J, Wang R et. al.
May 3rd, 2021 - The objective of this study is to describe the clinical features of patients with axial spondyloarthritis (axial SpA) in the ChinaSpA registry. Patients with clinical diagnosis of ankylosing spondylitis (AS) or axial SpA were enrolled into the reg...
https://doi.org/10.1007/s10067-021-05713-8
Clinical Rheumatology; Merola JF, Dennis N et. al.
May 2nd, 2021 - To compare healthcare resource utilization and costs among patients with psoriasis, psoriatic arthritis (PsA), and a control group of patients without psoriasis and PsA in the USA. The IBM® MarketScan® Commercial Database was used to identify thre...
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c16e7e43-3869-9fef-e053-2995a90a1fdb
May 2nd, 2021 - Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac. Use the lowest effective dose for the shortest duration consistent with individual pati...
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1b78c49-82e9-2402-e053-2a95a90ae35f
May 2nd, 2021 - CAREFULLY CONSIDER THE POTENTIAL BENEFITS AND RISKS OF NAPROXEN AND OTHER TREATMENT OPTIONS BEFORE DECIDING TO USE NAPROXEN TABLETS. USE THE LOWEST EFFECTIVE DOSE FOR THE SHORTEST DURATION CONSISTENT WITH INDIVIDUAL PATIENT TREATMENT GOALS (SEE WA...
News 771 results
https://www.staging.medscape.com/viewarticle/940709
Nov 9th, 2020 - Patients with active ankylosing spondylitis (AS) experienced rapid clinical response to the oral Janus kinase (JAK) inhibitor tofacitinib (Xeljanz) in a phase 3, randomized, double-blind, placebo-controlled study. Tofacitinib was significantly mor...
https://www.medscape.com/viewarticle/940709
Nov 9th, 2020 - Patients with active ankylosing spondylitis (AS) experienced rapid clinical response to the oral Janus kinase (JAK) inhibitor tofacitinib (Xeljanz) in a phase 3, randomized, double-blind, placebo-controlled study. Tofacitinib was significantly mor...
https://reference.medscape.com/viewarticle/932588_4
Jul 1st, 2020 - The age of onset of AS is usually from the late teens to 40 years. Onset in persons older than 50 years is unusual, although diagnosis of mild or asymptomatic disease may be made at a later age. Insidious onset of low back pain is the most common ...
https://reference.medscape.com/viewarticle/932588_1
Jul 1st, 2020 - Ankylosing spondylitis (AS) is a chronic, multisystem inflammatory disorder primarily affecting the axial skeleton and sacroiliac joints. AS is one of the seronegative spondyloarthropathies, which are multisystem inflammatory diseases that affect ...
https://reference.medscape.com/viewarticle/932588
Jul 1st, 2020 - Ankylosing spondylitis (AS) is a chronic, multisystem inflammatory disorder primarily affecting the axial skeleton and sacroiliac joints. AS is one of the seronegative spondyloarthropathies, which are multisystem inflammatory diseases that affect ...
